middle.news
How Alterity’s ATH434 Secured FDA Backing for Phase 3 in MSA
10:14am on Monday 30th of March, 2026 AEDT
•
Biotechnology
Read Story
How Alterity’s ATH434 Secured FDA Backing for Phase 3 in MSA
10:14am on Monday 30th of March, 2026 AEDT
Key Points
Positive FDA feedback on clinical pharmacology and non-clinical development
Alignment on key elements of ATH434 Phase 3 program
Plans to seek FDA agreement on manufacturing controls and trial design
End-of-Phase 2 meeting scheduled for mid-2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ALTERITY THERAPEUTICS (ASX:ATH)
OPEN ARTICLE